DE69926806D1 - N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren - Google Patents

N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren

Info

Publication number
DE69926806D1
DE69926806D1 DE69926806T DE69926806T DE69926806D1 DE 69926806 D1 DE69926806 D1 DE 69926806D1 DE 69926806 T DE69926806 T DE 69926806T DE 69926806 T DE69926806 T DE 69926806T DE 69926806 D1 DE69926806 D1 DE 69926806D1
Authority
DE
Germany
Prior art keywords
modulators
ureidoalkylpiperidines
activity
chemokin
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926806T
Other languages
English (en)
Inventor
S Ko
V Delucca
V Duncia
Tae Kim
B Santella
A Wacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DE69926806D1 publication Critical patent/DE69926806D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
DE69926806T 1998-12-18 1999-12-17 N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren Expired - Lifetime DE69926806D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11271798P 1998-12-18 1998-12-18
US16122199P 1999-10-22 1999-10-22
PCT/US1999/030334 WO2000035452A1 (en) 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
DE69926806D1 true DE69926806D1 (de) 2005-09-22

Family

ID=26810264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926806T Expired - Lifetime DE69926806D1 (de) 1998-12-18 1999-12-17 N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren

Country Status (17)

Country Link
US (1) US6444686B1 (de)
EP (1) EP1161240B1 (de)
JP (1) JP2002532427A (de)
KR (1) KR20010101287A (de)
CN (1) CN1206219C (de)
AT (1) ATE302005T1 (de)
AU (1) AU770042B2 (de)
BR (1) BR9917038A (de)
CA (1) CA2347770A1 (de)
DE (1) DE69926806D1 (de)
EA (1) EA003147B1 (de)
HK (1) HK1044282A1 (de)
IL (1) IL142768A0 (de)
NO (1) NO20012977L (de)
NZ (1) NZ511394A (de)
TR (1) TR200101859T2 (de)
WO (1) WO2000035452A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6441001B1 (en) 1998-12-18 2002-08-27 Bristol-Myers Squibb Pharma Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126600A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2003512349A (ja) 1999-10-15 2003-04-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのベンジルシクロアルキルアミン
AU1201101A (en) 1999-10-15 2001-04-30 Du Pont Pharmaceuticals Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
US6897234B2 (en) * 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
MXPA02012712A (es) 2000-06-30 2003-04-25 Bristol Myers Squibb Pharma Co N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
EP1324990B1 (de) 2000-09-29 2014-10-29 Glaxo Group Limited Morpholinacetamid-derivate zur behandlung von entzündlichen erkrankungen
KR20030061455A (ko) 2000-12-19 2003-07-18 에프. 호프만-라 로슈 아게 Ｃｃｒ-3 수용체 길항제로서의 치환된 피롤리딘
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
MXPA04005176A (es) * 2001-11-30 2004-08-11 Hoffmann La Roche N-ureido-piperidinas como antagonistas viii para receptores ccr-3.
JP2005516903A (ja) 2001-11-30 2005-06-09 エフ．ホフマン−ラ　ロシュ　アーゲー 喘息の処置におけるｃｃｒ−３受容体拮抗物質として使用するためのピペラジン誘導体
BR0214611A (pt) 2001-11-30 2004-09-14 Hoffmann La Roche Antagonistas vii de receptor ccr-3
US6977265B2 (en) 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
PT1471054E (pt) 2002-01-11 2009-09-23 Daiichi Sankyo Co Ltd Derivado de aminoálcool ou derivado de ácido fosfónico e composição medicinal que os contém
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
CA2503674A1 (en) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives
ATE384724T1 (de) * 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
US7351720B2 (en) * 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2007505080A (ja) * 2003-09-15 2007-03-08 ノバルティス アクチエンゲゼルシャフト 炎症性およびアレルギー性疾患の処置における、ｃｃｒ−３受容体アンタゴニストとして使用するための１，３−二置換アゼチジン誘導体
KR20070014108A (ko) * 2003-09-26 2007-01-31 액테리온 파마슈티칼 리미티드 피리딘 유도체 및 이의 우로텐신 ⅱ 길항제로서의 용도
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
NZ554555A (en) * 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
EP1889622A4 (de) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
CA2631232A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Novel vinylogous acids derivatives
EP1995246A4 (de) 2006-03-10 2010-11-17 Ono Pharmaceutical Co Nitrogeniertes heterocyclisches derivat und arzneimittel mit dem derivat als wirkstoff
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7705034B2 (en) 2006-10-13 2010-04-27 Hoffmann-La Roche Inc. Vinylogous acid derivatives
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8507534B2 (en) 2007-12-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN101910134B (zh) 2007-12-07 2014-03-19 沃泰克斯药物股份有限公司 环烷基甲酰氨基-吡啶苯甲酸类的生产方法
CN103382201B (zh) 2008-02-28 2016-12-28 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AR081069A1 (es) * 2010-04-07 2012-06-06 Vertex Pharma Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX2014001504A (es) 2011-08-08 2014-11-25 Thompson Boyce Plant Res Compuestos de moleculas pequeñas para el control de nematodos.
WO2013023000A2 (en) 2011-08-08 2013-02-14 California Institute Of Technology Small molecule compounds that control mammal-pathogenic nematodes
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
JP6618120B2 (ja) * 2014-08-06 2019-12-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
JP6898043B2 (ja) 2016-02-04 2021-07-07 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体
MA53755A (fr) 2016-03-17 2021-08-04 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité comme agonist de taar
EP3503904A4 (de) 2016-08-25 2020-03-25 California Institute of Technology Ascarosid-behandlung von eosinophiler ösophagitis
DK3557998T3 (da) * 2016-12-23 2023-11-20 Aquinnah Pharmaceuticals Inc Sammensætninger, kompositioner og anvendelsesmetoder
US20220235086A1 (en) 2019-05-17 2022-07-28 California Institute Of Technology Ascaroside derivatives and methods of use
CN117561238A (zh) * 2021-05-26 2024-02-13 住友制药株式会社 苯基脲衍生物
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461120A (en) 1965-09-27 1969-08-12 Sterling Drug Inc N-((1-piperidyl)-lower-alkyl)-n-((3-,2-,and 1-indolyl)-lower-alkyl) amines
GB8816365D0 (en) * 1988-07-08 1988-08-10 Pfizer Ltd Therapeutic agents
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
DK60693D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60893D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Piperidinderivater, deres fremstilling og anvendelse
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
EP0819001A1 (de) * 1995-04-05 1998-01-21 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
EP0861075A1 (de) 1995-11-13 1998-09-02 Albany Medical College Analgetische verbindungen und deren verwendung
ES2175161T3 (es) 1995-12-18 2002-11-16 Fujisawa Pharmaceutical Co Derivados de piperazina como antagonistas de taquiquinina.
AU712504B2 (en) 1996-01-30 1999-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025604A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998031364A1 (en) 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1086078B1 (de) 1998-06-08 2003-02-05 Schering Corporation Neuropeptid y5-rezeptorantagonisten
SE9802209D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds

Also Published As

Publication number Publication date
CN1335771A (zh) 2002-02-13
BR9917038A (pt) 2002-04-02
CN1206219C (zh) 2005-06-15
EP1161240B1 (de) 2005-08-17
ATE302005T1 (de) 2005-09-15
NZ511394A (en) 2003-07-25
JP2002532427A (ja) 2002-10-02
NO20012977L (no) 2001-08-20
US6444686B1 (en) 2002-09-03
KR20010101287A (ko) 2001-11-14
WO2000035452A1 (en) 2000-06-22
CA2347770A1 (en) 2000-06-22
AU1940600A (en) 2000-07-03
HK1044282A1 (zh) 2002-10-18
EP1161240A4 (de) 2002-04-03
EP1161240A1 (de) 2001-12-12
EA003147B1 (ru) 2003-02-27
IL142768A0 (en) 2002-03-10
NO20012977D0 (no) 2001-06-15
AU770042B2 (en) 2004-02-12
EA200100678A1 (ru) 2001-12-24
TR200101859T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
ATE233274T1 (de) Oxyiminopregnancarbolactone
FI950309A0 (fi) Proliiniamidijohdannaisia
BG66085B1 (bg) Фенилаланинови производни
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
WO2001028987A8 (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SE9901077D0 (sv) Novel use
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69614149T2 (de) Chinolinderivate als antimalariamittel
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
WO2005048932A3 (en) N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
NO20051013L (no) N-ureidoalkyl-piperidiner som modulerende forbindelser av kjemokinreseptor-aktivitet

Legal Events

Date Code Title Description
8332 No legal effect for de